News from CNBC Business
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Ceo
Investors
Shares
Tariffs
Stock
Stock Market
Crypto Assets
Cryptocurrency
Ethereum
Price
Markets
Xrp
Stablecoin
Etf
Investment
Bse
Blockchain
Ipo
Sec
Eth
Index
Solana
Trade
Inflation
Earnings
Interest Rates
Coinbase
Revenue
Token
Sensex
Wall Street
Nasdaq
China
Federal Reserve
Nse
Treasury
Traders
Bse Sensex
Gold
Sp 500
Nifty
Tesla
Economy
Profit
Usd
Investor
Co Founder
Nalco
Trojan
Kelloggs
Retail Chains
Chief Operations Officer
Mega Matrix Corp
Overcapacities
User Compensation Plan
Private Credit Markets
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search Cnbc Business headlines…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
CNBC Business • Jun 17, 2025
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting close...
Pharmaceutical companies are advancing the development of specialized cancer treatments, potentially reducing reliance on chemotherapy and driving significant market growth through...
Read Full Article →
CNBC Business • Jun 09, 2025
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck’s newly authorized RSV vaccine for infants is expected to impact the market by challenging established treatments, potentially influencing sales and market share among leadin...
Read Full Article →